6,7,8,9-tetrahydro-N,N-dipropyl-3H-benz[e]indol-8-amine | 83343-44-6

• 分子结构分类: 有机化合物 - 苯类化合物 - 四氢化萘
• 英文名称: 6,7,8,9-tetrahydro-N,N-dipropyl-3H-benz[e]indol-8-amine
• 英文别名: 6,7,8,9-tetrahydro-N,N-dipropyl-3H-benz(e)indole-8-amine；N,N-Dipropyl-6,7,8,9-tetrahydro-3H-benzo[e]indol-8-amine
• CAS: 83343-44-6
• 化学式: C₁₈H₂₆N₂
• 分子量: 270.418
• InChiKey: GKDJCOLVXBCNNK-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.6
• 重原子数：
  20
• 可旋转键数：
  5
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.56
• 拓扑面积：
  19
• 氢给体数：
  1
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  6,7,8,9-tetrahydro-N,N-dipropyl-3H-benz[e]indol-8-amine 生成 (S)-N,N-di-n-propyl-6,7,8,9-tetrahydro-3H-benzindol-8-ylamine
  参考文献：
  名称：

  (S)- and (R)-8-(di-n-propylamino)-6,7,8,9-tetrahydro-3H-benz[e]indole-1-carbaldehyde: a new class of orally active 5-HT1A-receptor agonists

  摘要：

  The enantiomers of 6,7,8,9-tetrahydro-N,N-di-n-propyl-3H-benz[e]indol-8-amine (S-(-)-2b and R-(+)-2b) and their corresponding 1-formyl analogs (S-(-)-6 and R-(+)-6) were prepared and evaluated pharmacologically for serotonergic and dopaminergic activity. The introduction of a formyl group in the 1-position shifted the pharmacological profile of 2b from a mixed D2/5-HT1A agonists to a selective 5-HT1A agonist (6). The enantiomers of 6 were agonists with full intrinsic activity and had an affinity comparable to that of 8-hydroxy-2-(di-n-propylamino)tetrahydronaphthalene (8-OH-DPAT). In contrast to 8-OH-DPAT, the enantiomers of compound 6 were found to have good oral availability.

  DOI：

  10.1021/jm00067a002
• 作为产物：
  描述：

  8-chloro-2-(N-n-propyl-N-propionyl-amino)-1,2,3,4-tetrahydronaphthalene 在 palladium on activated charcoal lithium aluminium tetrahydride 、 硫酸 、 盐酸羟胺 、 硝酸 、 甲酸铵 、 sodium sulfate 作用下， 以 甲醇 、 乙醚 、 硝基甲烷 、 水 为溶剂， 反应 19.0h， 生成 6,7,8,9-tetrahydro-N,N-dipropyl-3H-benz[e]indol-8-amine
  参考文献：
  名称：

  (S)- and (R)-8-(di-n-propylamino)-6,7,8,9-tetrahydro-3H-benz[e]indole-1-carbaldehyde: a new class of orally active 5-HT1A-receptor agonists

  摘要：

  The enantiomers of 6,7,8,9-tetrahydro-N,N-di-n-propyl-3H-benz[e]indol-8-amine (S-(-)-2b and R-(+)-2b) and their corresponding 1-formyl analogs (S-(-)-6 and R-(+)-6) were prepared and evaluated pharmacologically for serotonergic and dopaminergic activity. The introduction of a formyl group in the 1-position shifted the pharmacological profile of 2b from a mixed D2/5-HT1A agonists to a selective 5-HT1A agonist (6). The enantiomers of 6 were agonists with full intrinsic activity and had an affinity comparable to that of 8-hydroxy-2-(di-n-propylamino)tetrahydronaphthalene (8-OH-DPAT). In contrast to 8-OH-DPAT, the enantiomers of compound 6 were found to have good oral availability.

  DOI：

  10.1021/jm00067a002

文献信息

• Structure-Activity Relationships in the 8-Amino-6,7,8,9-tetrahydro-3H-benz[e]indole Ring System. Part 1: Effects of Substituents in the Aromatic System on Serotonin and Dopamine Receptor Subtypes
  作者：Peter Stjernloef、Michael D. Ennis、Lars O. Hansson、Robert L. Hoffman、Nabil B. Ghazal、Staffan Sundell、Martin W. Smith、Kjell Svensson、Arvid Carlsson、Hkan Wikstroem

  DOI：10.1021/jm00012a021

  日期：1995.6

  compounds were resolved. The substituents used in the 1-position were chosen from a principal component analysis (PCA) plot constructed from both tabulated variables and variables calculated by semiempirical methods (PM3) and molecular mechanics software (MMX). Among the analogs prepared, some, e.g., compound 21, were equipotent to compound 5 with respect to 5-HT1A effects. All compounds were more or

  一系列针对5-（1-丙基氨基）-6,7,8,9-四氢-3H-苯并[e]吲哚-1-甲醛的有效5-HT1A的1-，3-和4-取代基（5 ）制备并在5-HT1A，5-HT1Dα，5-HT1Dβ，D2和D3受体上进行体外测试，并在利血平预处理的大鼠中进行5-HTP和DOPA积累测定中的激动剂活性体内测试。一些化合物已解决。从主成分分析（PCA）图中选择在1位使用的取代基，该图由列表变量和通过半经验方法（PM3）和分子力学软件（MMX）计算的变量构成。在制备的类似物中，一些例如化合物21就5-HT1A作用而言与化合物5等价。所有化合物都对5-HT1A受体具有选择性，
• Centrally acting 6,7,8,9-tetrahydro-3H-benz(E)indole heterocyclics
  申请人：——

  公开号：US05461061A1

  公开（公告）日：1995-10-24

  A compound of Formula I ##STR1## or pharmaceutically acceptable salts of Formula I, where R.sup.1 is H, C.sub.1 -C.sub.3 alkyl, --(CH.sub.2).sub.n CONH.sub.2 where n is 2 to 6, (CH2).sub.n -1-(4,4-dimethylpiperidine-2,6-dione-yl), or cyclopropylmethyl; R.sup.2 is hydrogen, C.sub.1 -C.sub.8 alkyl, C.sub.3 -C.sub.8 cycloalkyl or combined with R.sup.1 to form a C.sub.3 -C.sub.8 cycloalkyl, C.sub.2 -C.sub.8 alkenyl, C.sub.2 -C.sub.8 akynyl, (CH.sub.2).sub.n --X--Ar where X is O, S, or NH, 3,3,3-trifluoropropyl, --(CH.sub.2).sub.m --R.sup.9 where m is 2 or 3 and R.sup.9 is phenyl, 2-thiophenyl or 3-thiophenyl; R.sup.3 is hydrogen, C.sub.1 -C.sub.3 alkyl, 2,2,2-trifluoroethyl, 3,3,3-trifluoropropyl, formyl, CN, halogen, CH.sub.2 OR.sup.2, C(O)C(O)OR.sup.1, C(O)CO NR.sup.1 R.sup.2, --(CH.sub.2).sub.q --NR.sup.1 R.sup.2 where q is 0 to 5, C.dbd.NOR.sup.2, 2(4,5-dihydro)oxazolyl, or COR.sup.10 where R.sup.10 is H, R.sup.1, NR.sup.1 R.sup.2 or CF.sub.3 ; R.sup.4 is hydrogen, C.sub.1 -C.sub.3 alkyl, cyclopropylmethyl, CF.sub.3, 2,2,2-trifluoroethyl, CN, CONR.sup.1 R.sup.2, .dbd.O, 2(4,5-dihydro)imidazolyl, 2(4,5-dihydro)oxazolyl, 2-oxazolyl, 3-oxadiazolyl, or 3,3,3-trifluoropropyl; R.sup.5 is hydrogen, R.sup. 1, OCH.sub.3, C(O)CH.sub.3 or C(O)OR.sup.1 ; X is (a) a valence bond, (b) CH.sub.2, or (c) O, S or NR.sup.5 where R.sup.5 is H, C.sub.1 -C.sub.8 alkyl, C.sub.3 -C.sub.8 cycloalkyl, benzyl, COR.sup.6 where R.sup.6 is a C.sub.1 -C.sub.3 alkyl, phenyl, or CONR.sup.7 R.sup.8 where R.sup.7 and R.sup.8 are independently H or C.sub.1 -C.sub.3 alkyl; and Z is a hydrogen or halogen; provided that when X is CH.sub.2, at least one of R.sub.3 and R.sub.4 is other than hydrogen or C.sub.1 -C.sub.3 alkyl. The compounds of Formula I are suitable for treating disorders of the central nervous system, particularly as 5-HT.sub.1A receptor agonists.

  公式I的化合物##STR1##或公式I的药用盐，其中R.sup.1为H、C.sub.1 -C.sub.3烷基、--(CH.sub.2).sub.n CONH.sub.2，其中n为2至6，(CH2).sub.n-1-(4,4-二甲基哌啶-2,6-二酮基)或环丙基甲基；R.sup.2为氢、C.sub.1 -C.sub.8烷基、C.sub.3 -C.sub.8环烷基或与R.sup.1结合形成C.sub.3 -C.sub.8环烷基、C.sub.2 -C.sub.8烯基、C.sub.2 -C.sub.8炔基、(CH.sub.2).sub.n--X--Ar，其中X为O、S或NH、3,3,3-三氟丙基、--(CH.sub.2).sub.m--R.sup.9，其中m为2或3，R.sup.9为苯基、2-噻吩基或3-噻吩基；R.sup.3为氢、C.sub.1 -C.sub.3烷基、2,2,2-三氟乙基、3,3,3-三氟丙基、甲酰基、CN、卤素、CH.sub.2 OR.sup.2、C(O)C(O)OR.sup.1、C(O)CO NR.sup.1 R.sup.2、--(CH.sub.2).sub.q--NR.sup.1 R.sup.2，其中q为0至5、C.dbd.NOR.sup.2、2(4,5-二氢)噁唑基或COR.sup.10，其中R.sup.10为H、R.sup.1、NR.sup.1 R.sup.2或CF.sub.3；R.sup.4为氢、C.sub.1 -C.sub.3烷基、环丙基甲基、CF.sub.3、2,2,2-三氟乙基、CN、CONR.sup.1 R.sup.2、.dbd.O、2(4,5-二氢)咪唑基、2(4,5-二氢)噁唑基、2-噁唑基、3-噁二唑基或3,3,3-三氟丙基；R.sup.5为氢、R.sup. 1、OCH.sub.3、C(O)CH.sub.3或C(O)OR.sup.1；X为(a)一个价键、(b)CH.sub.2或(c)O、S或NR.sup.5，其中R.sup.5为H、C.sub.1 -C.sub.8烷基、C.sub.3 -C.sub.8环烷基、苄基、COR.sup.6，其中R.sup.6为C.sub.1 -C.sub.3烷基、苯基或CONR.sup.7 R.sup.8，其中R.sup.7和R.sup.8独立地为H或C.sub.1 -C.sub.3烷基；Z为氢或卤素；但当X为CH.sub.2时，R.sub.3和R.sub.4中至少一个不是氢或C.sub.1 -C.sub.3烷基。公式I的化合物适用于治疗中枢神经系统疾病，特别是作为5-HT.sub.1A受体激动剂。
• Centrally acting 6,7,8,9-tetrahydro-3H-benz(e)indole heterocyclics
  申请人：The Upjohn Company

  公开号：US05288748A1

  公开（公告）日：1994-02-22

  A compound of Formula I ##STR1## or pharmaceutically acceptable salts of Formula I, where R.sup.1 is H, C.sub.1 -C.sub.3 alkyl, --(CH.sub.2).sub.n CONH.sub.2 where n is 2 to 6, (CH2).sub.n -1-(4,4-dimethylpiperidine-2,6-dione-yl), or cyclopropylmethyl; R.sup.2 is hydrogen, C.sub.1 -C.sub.8 alkyl, C.sub.3 -C.sub.8 cycloalkyl or combined with R.sup.1 to form a C.sub.3 -C.sub.8 cycloalkyl, C.sub.2 -C.sub.8 alkenyl, C.sub.2 -C.sub.8 akynyl, (CH.sub.2).sub.n --R"--Ar where R" is O, S, or NH, 3,3,3-trifluoropropyl, --(CH.sub.2).sub.m --R.sup.9 where m is 2 or 3 and R.sup.9 is phenyl, 2-thienyl or 3-thienyl; R.sup.3 is hydrogen, C.sub.1 -C.sub.3 alkyl, 2,2,2-trifluoroethyl, 3,3,3-trifluoropropyl, formyl, CN, halogen, CH.sub.2 OR.sup.2, C(O)C(O)OR.sup.1, C(O)CO NR.sup.1 R.sup.2, --(CH.sub.2).sub.q --NR.sup.1 R.sup.2 where q is 0 to 5, C.dbd.NOR.sup.2, 2(4,5-dihydro)oxazolyl, or COR.sup.10 where R.sup.10 is H, R.sup.1, NR.sup.1 R.sup.2 or CF.sub.3 ; R.sup.4 is hydrogen, C.sub.1 -C.sub.3 alkyl, cyclopropylmethyl, CF.sub.3, 2,2,2-trifluoroethyl, CN, CONR.sup.1 R.sup.2, .dbd.O, 2(4,5-dihydro)imidazolyl, 2(4,5-dihydro)oxazolyl, 2-oxazolyl, 3-oxadiazolyl, or 3,3,3-trifluoropropyl; R.sup.5 is hydrogen, R.sup.1, OCH.sub.3, C(O)CH.sub.3 or C(O)OR.sup.1 ; X is (a) a valence bond, (b) CH.sub.2, or (c) O, S or NR.sup.5 where R.sup.5 is H, C.sub.1 -C.sub.8 alkyl, C.sub.3 -C.sub.8 cycloalkyl, benzyl, COR.sup.6 where R.sup.6 is a C.sub.1 -C.sub.3 alkyl, phenyl, or CONR.sup.7 R.sup.8 where R.sup.7 and R.sup.8 are independently H or C.sub.1 -C.sub.3 alkyl; and Z is a hydrogen or halogen; provided that when X is CH.sub.2, at least one of R.sub.3 and R.sub.4 is other than hydrogen or C.sub.1 -C.sub.3 alkyl. The compounds of Formula I are suitable for treating disorders of the central nervous system, particularly as 5-HT.sub.1A receptor agonists.

  Formula I的化合物或Formula I的药学上可接受的盐，其中R.sup.1为H，C.sub.1-C.sub.3烷基，--(CH.sub.2).sub.n CONH.sub.2，其中n为2至6，(CH2).sub.n-1-(4,4-二甲基哌啶-2,6-二酮基)，或环丙甲基；R.sup.2为氢，C.sub.1-C.sub.8烷基，C.sub.3-C.sub.8环烷基或与R.sup.1结合形成C.sub.3-C.sub.8环烷基，C.sub.2-C.sub.8烯基，C.sub.2-C.sub.8炔基，(CH.sub.2).sub.n--R"--Ar，其中R"为O，S或NH，3,3,3-三氟丙基，--(CH.sub.2).sub.m--R.sup.9，其中m为2或3，R.sup.9为苯基、2-噻吩基或3-噻吩基；R.sup.3为氢，C.sub.1-C.sub.3烷基，2,2,2-三氟乙基，3,3,3-三氟丙基，甲酰基，CN，卤素，CH.sub.2OR.sup.2，C(O)C(O)OR.sup.1，C(O)CO NR.sup.1 R.sup.2，--(CH.sub.2).sub.q--NR.sup.1 R.sup.2，其中q为0至5，C.dbd.NOR.sup.2，2(4,5-二氢)噁唑基，或COR.sup.10，其中R.sup.10为H，R.sup.1，NR.sup.1 R.sup.2或CF.sub.3；R.sup.4为氢，C.sub.1-C.sub.3烷基，环丙甲基，CF.sub.3，2,2,2-三氟乙基，CN，CONR.sup.1 R.sup.2，.dbd.O，2(4,5-二氢)咪唑基，2(4,5-二氢)噁唑基，2-噁唑基，3-噁二唑基，或3,3,3-三氟丙基；R.sup.5为氢，R.sup.1，OCH.sub.3，C(O)CH.sub.3或C(O)OR.sup.1；X为(a)一个价键，(b)CH.sub.2，或(c)O，S或NR.sup.5，其中R.sup.5为H，C.sub.1-C.sub.8烷基，C.sub.3-C.sub.8环烷基，苄基，COR.sup.6，其中R.sup.6为C.sub.1-C.sub.3烷基，苯基，或CONR.sup.7 R.sup.8，其中R.sup.7和R.sup.8独立地为H或C.sub.1-C.sub.3烷基；Z为氢或卤素；但当X为CH.sub.2时，R.sub.3和R.sub.4中至少有一个不是氢或C.sub.1-C.sub.3烷基。Formula I的化合物适用于治疗中枢神经系统疾病，特别是作为5-HT.sub.1A受体激动剂。
• 6,7,8,9-Tetrahydro-N,N-di-n-propyl-3H-benzindol-8-amines. Derivatives as Potent and Orally Active Serotonin 5-HT1A Receptor Agonists
  作者：Peter Stjernloef、Thomas Elebring、Jonas Nilsson、Bengt Andersson、Soeren Lagerkvist、Kjell Svensson、Agneta Ekman、Arvid Carlsson、Haakan Wikstroem

  DOI：10.1021/jm00046a010

  日期：1994.9

  Derivatives and isosteric derivatives of the potent 5-HT1A agonist 8-(di-n-propylamino)-6,7,8,9-tetrahydro-3H-benz[e]indole- 1-carbaldehyde (5) were prepared and evaluated in vivo and in vitro for serotonergic and dopaminergic activity. The 1-cyano analog 8 was found to be almost equipotent to 5 and the previously described 2-cyano derivative 6, while a I-chloro and 1-(1,1,1-trifluoroethyl) substituent (9 and 10, respectively) formed less potent derivatives. The isosteric 6,7,8,9-tetrahydro-1H-benz[g]indoles 4 and 12-15 showed surprisingly low affinity or activity at both serotonergic and dopaminergic systems. The interpretations of these results by means of drug-receptor interactions at the 5-HT1A subtype are discussed. Compounds 6 and 8 were found to have high oral bioavailability in the rat (63% and 54%, respectively).
• Drug design via pharmacophore identification. Dopaminergic activity of 3H-benz[e]indol-8-amines and their mode of interaction with the dopamine receptor
  作者：Andre A. Asselin、Leslie G. Humber、Katherine Voith、Geoffrey Metcalf

  DOI：10.1021/jm00155a011

  日期：1986.5

  The design and synthesis of a series of 3H-benz[e]indol-8-amines are described. Two of the compounds are potent, orally active dopaminergic agents as established by their ability to induce contralateral turning in rats with unilateral 6-hydroxydopamine-induced lesions of the nigrostriatal pathway, to induce ambulation in rats rendered akinetic by bilateral injections of 6-hydroxydopamine into the anterolateral hypothalamus, and to antagonize reserpine-induced catalepsy in mice. The dopamine agonist activity of the 3H-benz[e]indol-8-amines establishes that a pyrrolo ring and a phenolic hydroxyl group can interact similarly with the dopamine receptor and provides evidence for the existence of a hydrogen-bond acceptor nucleus on the dopamine receptor macromolecule that is involved in the behavioral manifestations of dopamine agonists.